Optimal therapy for acute respiratory viral infections in infants and pre-primary children

Abstract

Aim. To study the effectiveness of a combined immunomodulatory drug consisting of complex immunoglobulin preparation and recombinant interferon-α2b in children of the first three years.Materials and methods. There were examined 55 children with acute respiratory viral infection of the upper respiratory tract from 2 months to 3 years. Of these, the main group consisted of 30 children receiving, as part of complex therapy, a combined immunomodulatory drug (Kipferon) in the form of rectal suppositories for children under one year old – 1 suppository per day, for children over one year old – 1 suppository twice a day for 5–7 days. The comparison group included 25 children receiving symptomatic therapy for acute respiratory viral infection, which did not differ in the compared groupsResults. It was revealed that the prescription of a combined immunomodulatory drug leads to a positive clinical effect in 90.0% of cases. While taking the drug, there is a more rapid relief of fever and symptoms of intoxication, as well as local inflammatory manifestations of acute respiratory viral infection (hyperemia of the pharynx, rhinitis, cough), which led to a shortening of the duration of the disease by 1.3 times and a reduction in the need for antibiotics by 2.4 times.Discussion. The results of the study, which showed significant advantages of including a combined immunomodulatory drug in the acute respiratory viral infection treatment regimen, are comparable with the available literature data.Conclusions. Considering the high clinical efficacy and safety of the combined immunomodulatory drug Kipferon, it can be recommended for widespread practical use in acute respiratory viral infections of the upper respiratory tract in young children.